{"id":"NCT01478971","sponsor":"Takeda","briefTitle":"Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis","officialTitle":"A Phase 3b Single-Arm, Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-11-24","resultsPosted":"2014-05-26","lastUpdate":"2016-09-20"},"enrollment":184,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease","Anemia"],"interventions":[{"type":"DRUG","name":"Epoetin","otherNames":[]},{"type":"DRUG","name":"Peginesatide","otherNames":["Omontys"]}],"arms":[{"label":"peginesatide injection","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to understand the effects of a dialysis center switching its dialysis patients from using Epoetin alfa to peginesatide injection on hemoglobin levels and other parameters.","primaryOutcome":{"measure":"Percentage of Participants Undergoing Conversion to Peginesatide Injection","timeFrame":"6 months","effectByArm":[{"arm":"Peginesatide Injection","deltaMin":88,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":178},"commonTop":["Pain in extremity","Arteriovenous fistula site complication","Fall","Diarrhoea","Vomiting"]}}